Aegis Capital initiated coverage of IntelGenx (OTCQX:IGXT) with a “buy” rating and $3 price target. The stock closed at 88 cents on Jan. 26.Read More
Health Canada has cleared IntelGenx’s (OTCQX:IGXT; TSXV:IGX) clinical trial application for its Montelukast VersaFilm intended for the treatment of mild-to- moderate Alzheimer's disease (AD).Read More
An article published in the journal, Immunity & Aging, suggests that the leukotriene receptor antagonist, Montelukast, rejuvenates aged brains in rats.Read More
IntelGenx (OTCQX:IGXT; TSXV:IGX;) has received a notice of allowance from the U.S. Patent and Trademark Office for a patent application entitled, “Solid oral film dosage forms and methods for making same.”Read More
An article on the Alzaforum website highlights IntelGenx (OTCQX:IGXT; TSXV:IGX) and its montelukast oral film candidate for the treatment of brain degenerative diseases, such as early-stage dementia.Read More
IntelGenx (OTCQX:IGXT; TSX-V:IGX) and RedHill Biopharma (NASDAQ, TASE:RDHL) announced that the Ministry of Health of Luxembourg has granted national marketing authorization for RIZAPORT (5 mg and 10 mg), an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines.Read More
IntelGenx (OTCQX:IGXT; TSX-V:IGX) has sold its royalty on future sales of Forfivo XL to SWK Holdings for $6-million.
Forfivo XL (bupropion extended release) is the first 450-milligram bupropion hydrogen chloride tablet indicated for major depressive disorder approved by the FDA. Patent protection for Forfivo XL in the U.S. expires in 2027, with an authorized generic entering the market in January 2018.Read More